Increased Brain Neurotensin and NTSR2 Lead to Weak Nociception in NTSR3/Sortilin Knockout Mice

The neuropeptide neurotensin (NT) elicits numerous pharmacological effects through three different receptors (NTSR1, NTSR2, and NTSR3 also called sortilin). Pharmacological approaches and generation of NTSR1 and NTSR2-deficient mice allowed to determine the NT-induced antipsychotic like behavior, th...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in neuroscience Vol. 10; p. 542
Main Authors Devader, Christelle, Moreno, Sébastien, Roulot, Morgane, Deval, Emmanuel, Dix, Thomas, Morales, Carlos R, Mazella, Jean
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Research Foundation 24.11.2016
Frontiers Media S.A
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The neuropeptide neurotensin (NT) elicits numerous pharmacological effects through three different receptors (NTSR1, NTSR2, and NTSR3 also called sortilin). Pharmacological approaches and generation of NTSR1 and NTSR2-deficient mice allowed to determine the NT-induced antipsychotic like behavior, the inhibitory of weak fear memory and the nociceptive signaling in a rat formalin tonic pain model to NTSR1. Conversely, the effects of NT on thermal and tonic nociceptions were mediated by NTSR2. However, the role of NTSR3/sortilin on the neurotensinergic system was not investigated. Here, by using C57Bl/6J mouse model in which the gene coding for NTSR3/sortilin has been inactivated, we observed a modification of the expression of both NTSR2 and NT itself. Quantitative PCR and protein expression using Western blot analyses and AlphaLisa™ technology resulted in the observation that brain NTSR2 as well as brain and blood NT were 2-fold increased in KO mice leading to a resistance of these mice to thermal and chemical pain. These data confirm that NTSR3/sortilin interacts with other NT receptors (i.e., NTSR2) and that its deletion modifies also the affinity of this receptor to NT.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience
Reviewed by: Andrew L. Gundlach, Florey Institute of Neuroscience and Mental Health, Australia; Dasiel Oscar Borroto-Escuela, Karolinska Institutet, Sweden
Edited by: Pascal Bonaventure, Janssen Research and Development, LLC, USA
ISSN:1662-4548
1662-453X
1662-453X
DOI:10.3389/fnins.2016.00542